Immuron Limited (NASDAQ: IMRN) shares leaped 22.29% to 8.56 following no new advances have been announced by Biotech. But the benefit from Immuron undoubtedly represented the continuing confidence of some investors.
Usually, investors do not put much emphasis on major profits or losses, for that matter, on no information.
On a traditionally low-volume trading day, such movements are mostly just noise. What truly matters, regardless of transient price fluctuations, are the growth opportunities of the firm.
The last official update by the Australian biopharma corporation focusing on the production and commercialization of oral immunotherapeutics for the treatment of gut-mediated diseases was on November 24, 2020, that it had earned a cash rebate of AUD $358,280 for qualifying research and development under the Australian Government’s Research and Development Income Tax Concession reward scheme.
The directors of Immuron Limited have approved this publication.
